FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF	CHANGES IN	BENEFICIAL	OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ALAM JOHN J (Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED			V	VERTEX PHARMACEUTICALS INC / MA [VRTX]									k all applicable) Director Officer (give title below)		10% O		Owner (specify		
				3. Date of Earliest Transaction (Month/Day/Year) 08/27/2008										EVP, Med. Dev. Group & CMO					
130 WAV	ERLY STI	REET			4. I	f Amen	dmer	nt, Date	of Origin	nal Fil	led (Month/Da	ay/Year)		Indiv	vidual or .	Joint/Group	Filinç	(Check Ap	plicable
(Street) CAMBR	IDGE M	A	01239		_									X		iled by Mor	•	orting Person One Repo	
(City)	(Si	tate)	(Zip)																
		Tab	le I - N	lon-Deri	vative	Sec	uriti	ies Ad	quire	d, D	isposed c	f, or B	eneficia	lly	Owned	ł			
Date		2. Transac Date (Month/Da	y/Year) if an		A. Deemed xecution Date, any Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar			nd 5) Securi Benefi Owned		es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	tion(s)			(Instr. 4)
Common Stock 08/27/			08/27/2	2008				М		6,612	A	\$10.1	9	143,404			D		
Common	Stock			08/27/2	2008				S ⁽¹⁾		6,612	D	\$27.020	2)(3)	136	5,792		D	
Common	Stock														5,140			I	401(k)
		Т	able I								posed of, , converti				wned				
Security or Exercise (Month/Day/Year) if any		emed 4. Transa Code (I /Day/Year) 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		ate	7. Title and Amount of Securities Underlying Derivative Sect (Instr. 3 and 4)		De Se (Ir	3. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s ully	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares						
Stock	\$10.19	08/27/2008			M			6,612	(4)		09/16/2008	Commor	6,612		\$ <mark>0</mark>	13,226	5	D	

Explanation of Responses:

- 1. Transaction for sales of common stock made pursuant to Dr. Alam's company approved trading plan established under Rule 10b5-1.
- 2. Open market sales reported on this line occurred at a weighted average price of \$27.02 (range \$26.70 to \$27.47).
- 3. Dr. Alam undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Fully vested.

Remarks:

Option

Kenneth S. Boger, Attorney-In-08/28/2008

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.